Zailong Wang

1.0k total citations
20 papers, 762 citations indexed

About

Zailong Wang is a scholar working on Rheumatology, Molecular Biology and Hematology. According to data from OpenAlex, Zailong Wang has authored 20 papers receiving a total of 762 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Rheumatology, 6 papers in Molecular Biology and 6 papers in Hematology. Recurrent topics in Zailong Wang's work include Spondyloarthritis Studies and Treatments (6 papers), Autoimmune and Inflammatory Disorders Research (6 papers) and Renal Transplantation Outcomes and Treatments (5 papers). Zailong Wang is often cited by papers focused on Spondyloarthritis Studies and Treatments (6 papers), Autoimmune and Inflammatory Disorders Research (6 papers) and Renal Transplantation Outcomes and Treatments (5 papers). Zailong Wang collaborates with scholars based in United States, Australia and United Kingdom. Zailong Wang's co-authors include Wenjing Lü, Ann Eldred, Ahmed M. Soliman, Kim Papp, Alan Kivitz, Stephen Hall, Philip J. Mease, Arthur Kavanaugh, Shephard Mpofu and Robert Brown and has published in prestigious journals such as Clinical Cancer Research, Biometrics and Annals of the Rheumatic Diseases.

In The Last Decade

Zailong Wang

19 papers receiving 754 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zailong Wang United States 12 283 267 225 191 122 20 762
E. Westphal Germany 11 261 0.9× 31 0.1× 84 0.4× 41 0.2× 39 0.3× 36 513
Dao X. Nguyen United Kingdom 9 236 0.8× 121 0.5× 69 0.3× 64 0.3× 16 0.1× 9 410
A. D. Hess United States 15 274 1.0× 25 0.1× 102 0.5× 239 1.3× 31 0.3× 31 597
Katrin Baumann Finland 6 488 1.7× 23 0.1× 164 0.7× 33 0.2× 33 0.3× 7 672
Carlo Moll Switzerland 7 141 0.5× 48 0.2× 272 1.2× 38 0.2× 7 0.1× 10 515
Christine Vogtenhuber United States 7 740 2.6× 26 0.1× 102 0.5× 126 0.7× 18 0.1× 7 866
Lidia De Felice Italy 13 175 0.6× 28 0.1× 222 1.0× 485 2.5× 34 0.3× 33 701
LD Notarangelo Italy 13 254 0.9× 24 0.1× 97 0.4× 137 0.7× 36 0.3× 19 534
Ana Sureda Spain 10 127 0.4× 41 0.2× 126 0.6× 328 1.7× 24 0.2× 15 544
H van Kamp Netherlands 15 159 0.6× 28 0.1× 266 1.2× 483 2.5× 6 0.0× 25 883

Countries citing papers authored by Zailong Wang

Since Specialization
Citations

This map shows the geographic impact of Zailong Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zailong Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zailong Wang more than expected).

Fields of papers citing papers by Zailong Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zailong Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zailong Wang. The network helps show where Zailong Wang may publish in the future.

Co-authorship network of co-authors of Zailong Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Zailong Wang. A scholar is included among the top collaborators of Zailong Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zailong Wang. Zailong Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Östör, Andrew J.K., Filip Van den Bosch, Kim Papp, et al.. (2022). Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study. Lara D. Veeken. 62(6). 2122–2129. 22 indexed citations
4.
Zhang, Lanju, Zailong Wang, Li Wang, et al.. (2022). A Simple Approach to Incorporating Historical Control Data in Clinical Trial Design and Analysis. Statistics in Biosciences. 14(2). 216–236. 3 indexed citations
5.
Kristensen, Lars Erik, Mauro Waldemar Keiserman, Kim Papp, et al.. (2021). Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. Annals of the Rheumatic Diseases. 81(2). 225–231. 99 indexed citations
6.
Östör, Andrew J.K., Filip Van den Bosch, Kim Papp, et al.. (2021). Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial. Annals of the Rheumatic Diseases. 81(3). 351–358. 79 indexed citations
7.
Kavanaugh, Arthur, Iain B. McInnes, Philip J. Mease, et al.. (2016). Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study. The Journal of Rheumatology. 43(9). 1713–1717. 65 indexed citations
8.
Kavanaugh, Arthur, Philip J. Mease, Andreas Reimold, et al.. (2016). Secukinumab for Long‐Term Treatment of Psoriatic Arthritis: A Two‐Year Followup From a Phase III, Randomized, Double‐Blind Placebo‐Controlled Study. Arthritis Care & Research. 69(3). 347–355. 64 indexed citations
9.
Mease, Philip J., Iain B. McInnes, Bruce Kirkham, et al.. (2015). Secukinumab Provides Sustained Improvements in Psoriatic Arthritis: 2-Year Efficacy and Safety Results from a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial. Queensland's institutional digital repository (The University of Queensland). 67. 2576–2578. 4 indexed citations
10.
Carmellini, Mario, Valter Duro Garcı́a, Zailong Wang, Marcela Vergara, & Graeme R. Russ. (2015). Efficacy of everolimus with reduced-exposure cyclosporine in de novo kidney transplant patients at increased risk for efficacy events: analysis of a randomized trial. Journal of Nephrology. 28(5). 633–639. 12 indexed citations
11.
Colussi, Giacomo, Marcela Vergara, Zailong Wang, & Róbert Roland. (2015). Risk factors associated with efficacy outcomes in kidney transplantation: analysis of a contemporary cohort of patients from the A2309 trial. Clinical Nephrology. 83 (2015)(6). 338–344. 8 indexed citations
12.
Chen, Xiulan, Ting Zhao, Jia‐Lin Wang, et al.. (2015). Quantitative Proteomic Analyses of Molecular Mechanisms Associated with Cytoplasmic Incompatibility in Drosophila melanogaster Induced by Wolbachia. Journal of Proteome Research. 14(9). 3835–3847. 36 indexed citations
13.
Cibrik, Diane M., Hélio Tedesco‐Silva, Anantharaman Vathsala, et al.. (2013). Randomized Trial of Everolimus-Facilitated Calcineurin Inhibitor Minimization Over 24 Months in Renal Transplantation. Transplantation. 95(7). 933–942. 83 indexed citations
14.
Shihab, Fuad S., Diane M. Cibrik, Laurence Chan, et al.. (2012). Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine. Clinical Transplantation. 27(2). 217–226. 33 indexed citations
15.
Lin, Shili, et al.. (2007). Serial analysis of gene expression profiles of adult and aged mouse cerebellum. Neurobiology of Aging. 29(5). 774–788. 5 indexed citations
16.
17.
Wang, Zailong, et al.. (2007). Heritable clustering and pathway discovery in breast cancer integrating epigenetic and phenotypic data. BMC Bioinformatics. 8(1). 38–38. 10 indexed citations
18.
Wei, Susan, Curtis Balch, Henry Paik, et al.. (2006). Prognostic DNA Methylation Biomarkers in Ovarian Cancer. Clinical Cancer Research. 12(9). 2788–2794. 118 indexed citations
19.
Verducci, Joseph S., et al.. (2006). Microarray analysis of gene expression: considerations in data mining and statistical treatment. Physiological Genomics. 25(3). 355–363. 55 indexed citations
20.
Chan, Michael W.Y., Susan Wei, Ping Wen, et al.. (2005). Hypermethylation of 18S and 28S Ribosomal DNAs Predicts Progression-Free Survival in Patients with Ovarian Cancer. Clinical Cancer Research. 11(20). 7376–7383. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by E. Westphal Breakdown of academic impact, for papers by Dao X. Nguyen Breakdown of academic impact, for papers by A. D. Hess Breakdown of academic impact, for papers by Katrin Baumann Breakdown of academic impact, for papers by Carlo Moll Breakdown of academic impact, for papers by Christine Vogtenhuber Breakdown of academic impact, for papers by Lidia De Felice Breakdown of academic impact, for papers by LD Notarangelo Breakdown of academic impact, for papers by Ana Sureda Breakdown of academic impact, for papers by H van Kamp
Rankless by CCL
2026